NCT05458232撤回不适用
Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Change in maximal voluntary contraction of lower leg.
研究概览
简要总结
This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 60 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Ages 60-75 yrs
- •Recently prescribed 5mg of tadalafil daily for clinical purposes
排除标准
- •History of diabetes
- •history of hypotension including orthostatic hypotension
- •History of malignancy or chemo/radiation therapy in the 6 months prior to enrollment
- •History of short gut syndrome, gastrointestinal bypass/reduction surgery (Lap band, gastric sleeve, etc.)
- •Subjects who cannot refrain from using protein or amino acid supplements for 7 days prior to Visit 2 and
- •Alcohol consumption of ≥ 5 units/servings per day
- •Concomitant use of
- •oral or injectable corticosteroids
- •testosterone, insulin like growth factor-1, or similar anabolic agent
- •riociguat (Adempas)
- •nitroglycerin
- •isosorbide dinitrate (Isordil)
- •isosorbide mononitrate (Imdur, Monoket)
- •doxazosin (Cardura)
- •prazosin (Minipress)
- •terazosin (Hytrin)
- •Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician
研究组 & 干预措施
5mg tadalafil once daily for 14 days
干预措施: Tadalafil 5mg (Drug)
结局指标
主要结局
Change in maximal voluntary contraction of lower leg.
时间窗: 14 days
Lower leg strength using a dynamometer; performed both before and after 14 days of tadalafil
次要结局
- Change in muscle Fatigue(14 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phosphodiesterase-5 Inhibitor in Eisenmenger SyndromeEisenmenger SyndromeNCT01200732Govind Ballabh Pant Hospital28
撤回
不适用
Efficacy of Type-5 Phosphodiesterase Inhibitors in Primary and Secondary Pulmonary HypertensionPrimary and Secondary Pulmonary HypertensionNCT00155714National Taiwan University Hospital20
终止
早期 1 期
Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain MetastasesBrain NeoplasmsBrain MetastasisGliomaNCT02279992Cedars-Sinai Medical Center7
已完成
3 期
Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and FunctionHeart Defects, CongenitalTransposition of Great Vessels With Ventricular InversionNCT03049540Insel Gruppe AG, University Hospital Bern100
已完成
2 期
Apremilast for Atopic Dermatitis - A Pilot Study in AdultsAtopic DermatitisNCT01393158Oregon Health and Science University16